search
Back to results

CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia

Primary Purpose

Pneumonia

Status
Completed
Phase
Phase 2
Locations
Nepal
Study Type
Interventional
Intervention
Zinc
Sponsored by
Centre For International Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pneumonia focused on measuring Child, pneumonia, Zinc, clinical trial, Nepal, nutrition, therapeutic

Eligibility Criteria

2 Months - 3 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Pneumonia: Child presenting with cough or difficult breathing and elevated respiratory rate. Severe pneumonia: Child presenting with cough or difficult breathing and chest indrawing , but without any of the following danger signs: not able to drink/breastfeed, vomit everything, has had convulsions, is lethargic or unconscious. Must be able to take Zinc Exclusion Criteria: The child requires special care for severe illness other than pneumonia Severe malnutrition defined as being < 70% National Center for Health Statistics (NCHS) median weight for height Presence of congenital heart disease Documented tuberculosis Any antibiotic treatment during the last 48 hours The child was enrolled less than 6 months ago Presence of dysentery Cough for more than 14 days

Sites / Locations

  • Siddhi Memorial Hospital (SMH),Bhelukhel, Bhimsensthan

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Zinc

Placebo

Arm Description

Zinc sulphate 10 or 20 mg (elemental zinc) per day. Intervention and placebo given perorally mixed with approximately 5 mL of breastmilk or clean water

Placebo

Outcomes

Primary Outcome Measures

Risk of Treatment Failure.
Enrolled children will be followed and given zinc or placebo for 14 days. We will compare the proportion with treatment failure (i.e. lack of improvement within 3 days) between the two groups
Non-injury Clinic Visits and Hospital Admissions After Treatment Has Been Initiated
We will measure to what extent the intervention can reduce the number of severe events.
Active and Passive Morbidity Surveillance for Six Months After the 14-day Supplementation Period is Completed
We will measure to what extent short term zinc administration has an impact on growth and morbidity for up to 6 months after end of supplementation
Difference in Growth and Thymic Size Between the Treatment Groups Measured at Three and Six Months After the Zinc Supplementation
Thymus size will be measured using ultrasonography and compared between the two groups. at two occasions 2.5 and 6 months after end of supplementation
Adverse Effects
Vomiting, regurgitation, pain in abdomen for 15 minutes after zinc or placebo administration.

Secondary Outcome Measures

Effect Modifiers for the Effect of Zinc Given During Pneumonia
We will also measure of there are factors at baseline that modifies the effect of zinc. Whether the following are modifiers for the above-mentioned effect of zinc given during pneumonia: i.severe inflammation, reflected in: high fever and/or elevated plasma C-reactive protein (CRP) concentration
The Efficacy of Zinc According to Breast Feeding Status and in Different Age Categories
We will measure to what extent breastfeeding status modifies the effect of zinc on pneumonia
The Efficacy of Zinc in Malnourished and Non-malnourished Children
We will compare the efficacy of zinc in those that are stunted, wasted or underweight with those who are not.
Will Presence of a RNA Virus Modify the Effect of Zinc
We will compare the efficacy of zinc according to virus detected in nasopharyngeal secretions
Folate, Cobalamin and Vitamin D Status of the Enrolled Children
And whether or not these vitamins predict treatment failure and duration of illness.

Full Information

First Posted
September 6, 2005
Last Updated
March 7, 2022
Sponsor
Centre For International Health
Collaborators
Tribhuvan University, Nepal, Statens Serum Institut, All India Institute of Medical Sciences, New Delhi, IRD, Epidemiologie et Prevention, Montpelier, France, Society for Applied Studies
search

1. Study Identification

Unique Protocol Identification Number
NCT00148733
Brief Title
CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia
Official Title
Community- and Health Facility-based Intervention With Zinc as Adjuvant Therapy for Pneumonia to Enhance Child Health and Nutrition
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
January 2004 (undefined)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
January 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Centre For International Health
Collaborators
Tribhuvan University, Nepal, Statens Serum Institut, All India Institute of Medical Sciences, New Delhi, IRD, Epidemiologie et Prevention, Montpelier, France, Society for Applied Studies

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The aim of the study described is to measure the degree with which zinc given as adjunct therapy to standard antibiotic treatment during childhood pneumonia reduces the risk of treatment failure and the duration of the illness.
Detailed Description
Hypothesis: Zinc deficiency is a major public health problem in developing counties. Poor zinc status is associated with stunted growth and reduced resistance to infections. Several in vitro experiments and in vivo studies in animals and humans have demonstrated detrimental effects of zinc depletion on almost all facets of the immune system. The epithelial linings in the gut and in the respiratory tract are important for the resistance to infections and continuous cell division is required for proper function of these barriers. Zinc is crucial for cellular division and for the maintenance of organs with cells with a rapid turnover, including epithelial cells. Clinical trials in children in developing countries have demonstrated improved growth and reduced prevalence of diarrhea and respiratory tract infections following zinc supplementation. Furthermore, zinc has a well-documented therapeutic effect when given during acute or persistent diarrhea. The effect of zinc may be explained by correction of a deficiency state and/or by a pharmacological, as yet poorly described, action. Due to the promising results from previous studies, WHO are now supporting large clinical trials in Nepal, India and Tanzania to assess whether routine zinc supplementation reduces mortality in early childhood. If the results of these trials show a mortality reduction, routine zinc supplementation or zinc dense foods may be promoted. However, while the first approach is logistically difficult and expensive, the second approach is difficult because zinc dense foods and foods with low phytic acid content are expensive and not readily available. Moreover, both approaches may be perceived to be incompatible with the current breast-feeding recommendations for the youngest children in most developing countries. There is limited information on zinc as adjunct therapy for pneumonia. A recent hospital-based study in young children with severe pneumonia, showed that the zinc group had a faster recovery, resulting in a shortening of stay in hospital of one day. However, this study was small and no community based study has been conducted so far. Whether zinc has an effect during respiratory infections has to be assessed in studies with larger sample sizes in children with less severe disease and should be repeated in children with more severe disease. Short-term zinc administration during infections may become an alternative or an addition to long-term supplementation or promotion of zinc dense foods. Furthermore, therapeutic administration of zinc will not interfere with the current breast-feeding recommendations. Hypothesis: Zinc as adjunct therapy for pneumonia may lead to faster recovery. Furthermore, long-term beneficial effects may include improved immuno-nutritional status measured by thymus size, less morbidity and improved growth. Comparison: Duration of illness, risk of treatment failure, for those with severe pneumonia: length of hospital stay. Number of non-injury clinic visits and hospitalizations during the intervention with Zinc and an in a 6 month period after enrolment. Growth assessed by anthropometry and thymus size assessed by ultrasonography. Explore the efficacy of zinc in etiology-sub groups including those defined by nutritional status, inflammation, fever, gender, breastfeeding status and viral etiology.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pneumonia
Keywords
Child, pneumonia, Zinc, clinical trial, Nepal, nutrition, therapeutic

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
2628 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Zinc
Arm Type
Experimental
Arm Description
Zinc sulphate 10 or 20 mg (elemental zinc) per day. Intervention and placebo given perorally mixed with approximately 5 mL of breastmilk or clean water
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
Zinc
Other Intervention Name(s)
Produced by Nutriset, Malaunay, France
Intervention Description
Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
Primary Outcome Measure Information:
Title
Risk of Treatment Failure.
Description
Enrolled children will be followed and given zinc or placebo for 14 days. We will compare the proportion with treatment failure (i.e. lack of improvement within 3 days) between the two groups
Time Frame
Within 2 weeks after enrollment
Title
Non-injury Clinic Visits and Hospital Admissions After Treatment Has Been Initiated
Description
We will measure to what extent the intervention can reduce the number of severe events.
Time Frame
Within 2 weeks after enrollment
Title
Active and Passive Morbidity Surveillance for Six Months After the 14-day Supplementation Period is Completed
Description
We will measure to what extent short term zinc administration has an impact on growth and morbidity for up to 6 months after end of supplementation
Time Frame
six months
Title
Difference in Growth and Thymic Size Between the Treatment Groups Measured at Three and Six Months After the Zinc Supplementation
Description
Thymus size will be measured using ultrasonography and compared between the two groups. at two occasions 2.5 and 6 months after end of supplementation
Time Frame
six months
Title
Adverse Effects
Description
Vomiting, regurgitation, pain in abdomen for 15 minutes after zinc or placebo administration.
Time Frame
14 days
Secondary Outcome Measure Information:
Title
Effect Modifiers for the Effect of Zinc Given During Pneumonia
Description
We will also measure of there are factors at baseline that modifies the effect of zinc. Whether the following are modifiers for the above-mentioned effect of zinc given during pneumonia: i.severe inflammation, reflected in: high fever and/or elevated plasma C-reactive protein (CRP) concentration
Time Frame
Within 2 weeks after enrollment
Title
The Efficacy of Zinc According to Breast Feeding Status and in Different Age Categories
Description
We will measure to what extent breastfeeding status modifies the effect of zinc on pneumonia
Time Frame
Within 2 weeks after enrollment
Title
The Efficacy of Zinc in Malnourished and Non-malnourished Children
Description
We will compare the efficacy of zinc in those that are stunted, wasted or underweight with those who are not.
Time Frame
Within 2 weeks after enrollment
Title
Will Presence of a RNA Virus Modify the Effect of Zinc
Description
We will compare the efficacy of zinc according to virus detected in nasopharyngeal secretions
Time Frame
14 days
Title
Folate, Cobalamin and Vitamin D Status of the Enrolled Children
Description
And whether or not these vitamins predict treatment failure and duration of illness.
Time Frame
14 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Months
Maximum Age & Unit of Time
3 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pneumonia: Child presenting with cough or difficult breathing and elevated respiratory rate. Severe pneumonia: Child presenting with cough or difficult breathing and chest indrawing , but without any of the following danger signs: not able to drink/breastfeed, vomit everything, has had convulsions, is lethargic or unconscious. Must be able to take Zinc Exclusion Criteria: The child requires special care for severe illness other than pneumonia Severe malnutrition defined as being < 70% National Center for Health Statistics (NCHS) median weight for height Presence of congenital heart disease Documented tuberculosis Any antibiotic treatment during the last 48 hours The child was enrolled less than 6 months ago Presence of dysentery Cough for more than 14 days
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tor A Strand, MD PhD
Organizational Affiliation
Centre for International Health, University of Bergen, 5021 Bergen, Norway
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Halvor Sommerfelt, MD PhD
Organizational Affiliation
Centre for International Health, University of Bergen, 5021 Bergen, Norway
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Prakash S Shrestha, MD Professor
Organizational Affiliation
Child Health Research Project, Department of Child Health, Institute of Medicine, Maharajganj
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Ramesh K Adhikari, MD Dean
Organizational Affiliation
Child Health Research Project, Department of Child Health, Institute of Medicine, Maharajganj
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Palle Valentiner-Branth, MD PhD
Organizational Affiliation
Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen S, Denmark
Official's Role
Principal Investigator
Facility Information:
Facility Name
Siddhi Memorial Hospital (SMH),Bhelukhel, Bhimsensthan
City
Bhaktapur
ZIP/Postal Code
P.O.Box 40
Country
Nepal

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
10586170
Citation
Bhutta ZA, Black RE, Brown KH, Gardner JM, Gore S, Hidayat A, Khatun F, Martorell R, Ninh NX, Penny ME, Rosado JL, Roy SK, Ruel M, Sazawal S, Shankar A. Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. J Pediatr. 1999 Dec;135(6):689-97. doi: 10.1016/s0022-3476(99)70086-7.
Results Reference
background
PubMed Identifier
7991643
Citation
Bates CJ, Prentice A. Breast milk as a source of vitamins, essential minerals and trace elements. Pharmacol Ther. 1994 Apr-May;62(1-2):193-220. doi: 10.1016/0163-7258(94)90011-6.
Results Reference
background
PubMed Identifier
7925188
Citation
Walsh CT, Sandstead HH, Prasad AS, Newberne PM, Fraker PJ. Zinc: health effects and research priorities for the 1990s. Environ Health Perspect. 1994 Jun;102 Suppl 2(Suppl 2):5-46. doi: 10.1289/ehp.941025.
Results Reference
background
PubMed Identifier
11986453
Citation
Strand TA, Chandyo RK, Bahl R, Sharma PR, Adhikari RK, Bhandari N, Ulvik RJ, Molbak K, Bhan MK, Sommerfelt H. Effectiveness and efficacy of zinc for the treatment of acute diarrhea in young children. Pediatrics. 2002 May;109(5):898-903. doi: 10.1542/peds.109.5.898.
Results Reference
background
PubMed Identifier
8457531
Citation
Bates CJ, Evans PH, Dardenne M, Prentice A, Lunn PG, Northrop-Clewes CA, Hoare S, Cole TJ, Horan SJ, Longman SC, et al. A trial of zinc supplementation in young rural Gambian children. Br J Nutr. 1993 Jan;69(1):243-55. doi: 10.1079/bjn19930026.
Results Reference
background
PubMed Identifier
9701163
Citation
Black RE. Therapeutic and preventive effects of zinc on serious childhood infectious diseases in developing countries. Am J Clin Nutr. 1998 Aug;68(2 Suppl):476S-479S. doi: 10.1093/ajcn/68.2.476S.
Results Reference
background
PubMed Identifier
9651405
Citation
Sazawal S, Black RE, Jalla S, Mazumdar S, Sinha A, Bhan MK. Zinc supplementation reduces the incidence of acute lower respiratory infections in infants and preschool children: a double-blind, controlled trial. Pediatrics. 1998 Jul;102(1 Pt 1):1-5. doi: 10.1542/peds.102.1.1.
Results Reference
background
PubMed Identifier
12052800
Citation
Bhandari N, Bahl R, Taneja S, Strand T, Molbak K, Ulvik RJ, Sommerfelt H, Bhan MK. Effect of routine zinc supplementation on pneumonia in children aged 6 months to 3 years: randomised controlled trial in an urban slum. BMJ. 2002 Jun 8;324(7350):1358. doi: 10.1136/bmj.324.7350.1358.
Results Reference
background
PubMed Identifier
9701153
Citation
Hambidge KM, Krebs NF, Miller L. Evaluation of zinc metabolism with use of stable-isotope techniques: implications for the assessment of zinc status. Am J Clin Nutr. 1998 Aug;68(2 Suppl):410S-413S. doi: 10.1093/ajcn/68.2.410S.
Results Reference
background
PubMed Identifier
10361260
Citation
Chai F, Truong-Tran AQ, Ho LH, Zalewski PD. Regulation of caspase activation and apoptosis by cellular zinc fluxes and zinc deprivation: A review. Immunol Cell Biol. 1999 Jun;77(3):272-8. doi: 10.1046/j.1440-1711.1999.00825.x.
Results Reference
background
PubMed Identifier
11264713
Citation
Truong-Tran AQ, Carter J, Ruffin R, Zalewski PD. New insights into the role of zinc in the respiratory epithelium. Immunol Cell Biol. 2001 Apr;79(2):170-7. doi: 10.1046/j.1440-1711.2001.00986.x.
Results Reference
background
PubMed Identifier
9701160
Citation
Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr. 1998 Aug;68(2 Suppl):447S-463S. doi: 10.1093/ajcn/68.2.447S.
Results Reference
background
PubMed Identifier
9701155
Citation
Lira PI, Ashworth A, Morris SS. Effect of zinc supplementation on the morbidity, immune function, and growth of low-birth-weight, full-term infants in northeast Brazil. Am J Clin Nutr. 1998 Aug;68(2 Suppl):418S-424S. doi: 10.1093/ajcn/68.2.418S.
Results Reference
background
PubMed Identifier
12042580
Citation
Bhandari N, Bahl R, Taneja S, Strand T, Molbak K, Ulvik RJ, Sommerfelt H, Bhan MK. Substantial reduction in severe diarrheal morbidity by daily zinc supplementation in young north Indian children. Pediatrics. 2002 Jun;109(6):e86. doi: 10.1542/peds.109.6.e86.
Results Reference
background
PubMed Identifier
15158629
Citation
Brooks WA, Yunus M, Santosham M, Wahed MA, Nahar K, Yeasmin S, Black RE. Zinc for severe pneumonia in very young children: double-blind placebo-controlled trial. Lancet. 2004 May 22;363(9422):1683-8. doi: 10.1016/S0140-6736(04)16252-1.
Results Reference
background
PubMed Identifier
8640039
Citation
Bhandari N, Bahl R, Hambidge KM, Bhan MK. Increased diarrhoeal and respiratory morbidity in association with zinc deficiency--a preliminary report. Acta Paediatr. 1996 Feb;85(2):148-50. doi: 10.1111/j.1651-2227.1996.tb13981.x.
Results Reference
background
PubMed Identifier
9250122
Citation
Sazawal S, Black RE, Bhan MK, Jalla S, Sinha A, Bhandari N. Efficacy of zinc supplementation in reducing the incidence and prevalence of acute diarrhea--a community-based, double-blind, controlled trial. Am J Clin Nutr. 1997 Aug;66(2):413-8. doi: 10.1093/ajcn/66.2.413.
Results Reference
background
PubMed Identifier
7651474
Citation
Sazawal S, Black RE, Bhan MK, Bhandari N, Sinha A, Jalla S. Zinc supplementation in young children with acute diarrhea in India. N Engl J Med. 1995 Sep 28;333(13):839-44. doi: 10.1056/NEJM199509283331304.
Results Reference
background
PubMed Identifier
8907767
Citation
Integrated management of the sick child. Bull World Health Organ. 1995;73(6):735-40.
Results Reference
background
PubMed Identifier
26407163
Citation
Haugen J, Chandyo RK, Brokstad KA, Mathisen M, Ulak M, Basnet S, Valentiner-Branth P, Strand TA. Cytokine Concentrations in Plasma from Children with Severe and Non-Severe Community Acquired Pneumonia. PLoS One. 2015 Sep 25;10(9):e0138978. doi: 10.1371/journal.pone.0138978. eCollection 2015.
Results Reference
derived
PubMed Identifier
20375190
Citation
Valentiner-Branth P, Shrestha PS, Chandyo RK, Mathisen M, Basnet S, Bhandari N, Adhikari RK, Sommerfelt H, Strand TA. A randomized controlled trial of the effect of zinc as adjuvant therapy in children 2-35 mo of age with severe or nonsevere pneumonia in Bhaktapur, Nepal. Am J Clin Nutr. 2010 Jun;91(6):1667-74. doi: 10.3945/ajcn.2009.28907. Epub 2010 Apr 7.
Results Reference
derived

Learn more about this trial

CHIZAP: Community- and Health Facility-Based Intervention With Zinc as Adjuvant Therapy for Childhood Pneumonia

We'll reach out to this number within 24 hrs